Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 9737 - 9744 of 12086 results
Privacy Monday - March 2, 2015: How is Your Cyber Resilience?
March 2, 2015| Blog| Viewpoint
In Case You Missed It: Health Care Enforcement in 2015 Webinar
March 2, 2015| Blog| Viewpoint
CMS Call Letter: Changes to and Implications of Star Ratings
March 2, 2015| Blog| Viewpoint
Please Join Us For Our Upcoming Webinar On Activist Shareholders
March 2, 2015| Blog| Viewpoint
FTC Looks to Accelerate Oncology Drug Growth by Requiring Novartis to Divest Two Protein Inhibitors in Its Clinical Development Pipeline
February 27, 2015| Alert| Viewpoint
More than Employees Bargained For: Do Union Employees Have a Right to Bargain Over Company Data Breaches?
February 27, 2015| Blog| Viewpoint
ICYMI: Privacy in the Workplace Webinar
February 27, 2015| Blog| Viewpoint
DHS Funded for One More Week; Shutdown Temporarily Averted
February 27, 2015| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|